廣聯達(002410.SZ):擬通過創元投資以1500萬元參投絲路科華
格隆匯4月13日丨廣聯達(002410.SZ)公佈,為緊跟科技前沿技術發展,推動企業技術進步與產品創新,廣聯達科技股份有限公司擬通過全資企業北京廣聯達創元投資中心(有限合夥)(簡稱“創元投資”)投資北京絲路科華股權投資中心(有限合夥)(簡稱“絲路科華”或“合夥企業”),並於近日簽署了《北京絲路科華股權投資中心(有限合夥)有限合夥協議》。
該合夥企業主要投資科技智能等領域的成長期、成熟期企業,目標規模為人民幣5億元。公司全資企業創元投資將作為有限合夥人,以自有資金1500萬元認購合夥企業份額,預計佔比不超過總規模的3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.